Global Antibody Drug Conjugates Market: By Type (Monoclonal Antibodies, Linkers), By Product (Adcertis, Kadcyla), By Application (Breast Cancer, Blood Cancer)- Forecast till 2032.
The report offers the value (in USD Million) for the above segments.
Global Antibody Drug Conjugates Market: By Type (Monoclonal Antibodies, Linkers), By Product (Adcertis, Kadcyla), By Application (Breast Cancer, Blood Cancer)- Forecast till 2032.
The report offers the value (in USD Million) for the above segments.
In 2023, the Antibody Drug Conjugates market was valued at USD 5,475.84 Million and is expected to reach USD 39,153.21 Million at the CAGR of 24.0% during 2024-2032.
Over the past few decades an antibody drug conjugate (ADC) medicines have advanced growing now 12 drugs have received global approval and over 140 ADCs are undergoing clinical trials. ADCs are specialist therapies that use the use of chemical connectors to join potent anti cancer drugs with monoclonal antibodies. An Improved pharmacokinetic and pharmacodynamic qualities as well as improved antibody engineering for accurate attachment have made ADCs more effective against a variety of diseases, including blood related malignancies and solid tumors.
The primary cause of this growth is the global rise in cancer incidence. Cancer Research UK has estimated that by 2040, there would be 27.5 million new cases of cancer worldwide, with smoking, poor diet, obesity, and alcohol use all contributing significantly to this number. On the other hand, the COVID-19 pandemic hurt the market since it resulted in fewer people purchasing products since less people had health insurance, fewer people visited hospitals, and fewer people were diagnosed. Furthermore, the prospective approval of ADCs like Adcetris for other applications was put on hold due to the lack of people for clinical trials.
The growth of new ADCs for the treatment of cancer is expected to drive market expansion, and major players including Roche , Piramal Pharma Solution, Pfizer, and Seagen Inc. are expected to increase their investment in this arena. For instance, in order to meet the increasing demand for commercial ADCs in the UK, CDMO Piramal Pharma Solutions (PPS) committed approximately USD 74.6 million in February 2022 to establish two new antibody-drug conjugates (ADC) production facilities at its existing sites in Grangemouth, Scotland. With this investment, PPS's position in the market is strengthened and its capacity to produce ADCs is greatly increased.
The majority of corporations carry out clinical trials in order to grow the label of previously approved products and introduce new items to the market. For example, in January 2022, patients with advanced solid tumors were enrolled in phase I clinical trials of two novel antibody-drug conjugates, SGN-B7H4V & SGN-PDL1V, by Seagen. Furthermore, the firm and Astellas completed patient recruitment for the cohort K EV-103 trial, which is intended to treat first-line metastatic urothelial cancer (mUC). Growth in the market is expected to be driven by the clinical trial study's successful conclusion and the goods' subsequent approval.
Market Snapshot
Market Size | · 2023: USD 5,475.84 Million · 2032: USD 39,153.21 Million |
CAGR | · 24.0% |
Key Market Drivers | · Rising Incidence and Prevalence of Cancer · Advancing Technology and Increasing Emphasis on Research and Development of ADCs · Increasing Investments and Government Support |
Key Market Challenges | · Side Effects of Cancer Treatments and Therapies |
Key Market Opportunities | · Huge Untapped Market opportunity |
Driver
Advancing Technology and Increasing Emphasis on Research and Development of ADCs
The treatment of cancer has experienced significant change as a result of technological advancements in drug discovery in which they have produced efficient choices like antibody drug conjugates (ADCs). Early and accurate detection of cancer has been made possible by the development of new diagnostic techniques such targeted radiation therapy, 3D mammography and CT scans. ADC market is being driven by large pharmaceutical and biotech businesses investing more in research and development of cancer drugs. American Association for Cancer Research has awarded over 634 grants and 5 million to more than 800 scientists to do research on a range of tumor types including those of the skin, gastrointestinal system, brain, bladder, prostate and breast. Companies are considering transactions as a means of increasing their market share in the ADC sector. To acquire all rights to the ADC medication Trodelvy (sacituzumab govitecan-hziy) which is used to treat metastatic triple-negative breast cancer, Gilead Sciences, Inc., for example, acquired Immunomedics. The worldwide market for ADCs is anticipated to gain from the increased emphasis on oncology medication research and development.
Advanced ADC Technology Supporting the Development of Next Generation ADCs
Antibody drug conjugates (ADCs) are a novel class of cancer treatment wherein a toxic agent is delivered directly to cancer cells also monoclonal antibodies. MMAE and DM4 are the two dangerous compounds that are used most often in ADCs. The majority of ADCs use linkers known as peptide linkers or valine citrulline (VC) linkers to connect these materials to the antibody.
Future developments in ADC technologies like precise site specific linking and novel linker types are anticipated to contribute to the markets expansion..
Restraints
Side Effects of Cancer Treatments and Therapies
The Antibody Drug Conjugates market is the expansion of indications beyond traditional cancer types. Initially, Antibody Drug Conjugates were primarily developed for hematological malignancies and solid tumors with well-defined targets. However, as research progresses and understanding of tumor biology improves, there's a growing interest in exploring ADCs for a broader range of cancers, including rare and difficult-to-treat malignancies. This trend is driven by advancements in target identification, antibody engineering, and conjugation technologies, allowing for the development of Antibody Drug Conjugates tailored to specific tumor types and molecular subtypes. Additionally, clinical trials evaluating the efficacy of Antibody Drug Conjugates in combination therapies or earlier lines of treatment contribute to the diversification of indications, potentially expanding the market reach and patient population for Antibody Drug Conjugates therapies.
A recent market research report added to repository of Intellectual Market Insights Research is an in-depth analysis of Global Antibody Drug Conjugates Market. On the basis of historic growth analysis and current scenario of Antibody Drug Conjugates market place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent tools that facilitate deeper understanding of multiple aspects of global Antibody Drug Conjugates market. This further helps users with their developmental strategy.
This report examines all the key factors influencing growth of global Antibody Drug Conjugates market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of global Antibody Drug Conjugates market unlocks a plethora of untapped opportunities in regional and domestic market places. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, pricing strategies, innovation possibilities and much more.
The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report will cover the qualitative and quantitative data on the global Antibody Drug Conjugates Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.
By Application (Lymphoma, Ovarian Cancer, Lung Cancer, Breast Cancer, Brain Tumor, and Others), By End User (Hospitals, Specialized Cancer Centers, Academic Research Institutes, Biotechnology Companies, and Others)
Roche, Abbvie Inc., Pfizer Inc., Takeda Pharmaceutical Company, Astellas Pharma, Concortis Biotherapeutics, Immunomedics, Inc., Antikor, Celldex Therapeutics, Genentech Inc.
Companies are continuously improvising the strategies and flooding the investments in order to tap the huge market. For instance, Biotechnology Company Antikor Biopharma Ltd is has formed strategic alliance with Essex Bio-Investment and entered into an Investment Agreement for up to US$3,100,000. Essex Bio-Investment a wholly-owned subsidiary of Essex Bio-Technology Ltd. This strategic move will enable Antikor to consolidate and expand its position as a leading innovator in smaller-format conjugate therapies for solid tumours.
Pipeline Products
US Trade Name (Generic Name) | Company | Current Status (US) | Molecular Target | Major Indication | Protein and Conjugate |
Trastuzumab emtansine (trastuzumab-DM1) | Genentech/Immunogen | Phase III (BLA filing expected in 2012) | HER2 | Breast cancer | Humanized IgG1 DM1 cytotoxin conjugate |
Inotuzumab ozogamicin (G5/44) | Wyeth | Phase III | CD22 | NHL | Humanized IgG4 calicheamicin cytotoxin conjugate |
Lorvotuzumab mertansine IMGN901 (formerly huN901 -DM1) | Immunogen | Phase II | CD56 | SCLC, MM | Humanized IgG-DM1 cytotoxin conjugate |
Glembatumumab vedotin (CDX-011; CR011 -vcMMAE) | Celldex (formerly CuraGen) | Phase II | GPNMB | Unresectable Stage III or Stage IV melanoma | Human IgG1 – MMAE cytotoxin conjugate |
CME-548 | Wyeth | Phase II | 5T4 | Solid tumors | IgG-calicheamicin cytotoxin conjugate |
IMGN242 | Immunogen | Phase II | CanAg | Oncology | Humanized IgG-DM4 cytotoxin conjugate |
The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2022-2031 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
By Drugs
By Application
By Mechanism Of Action
The report also helps in understanding Global Antibody Drug Conjugates Market dynamics, structure by analyzing the market segments, and project the Global Antibody Drug Conjugates Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Antibody Drug Conjugates Market make the report investor’s guide.
The market scope is segmented because of by Component, by Target, by Technology, by Application, By End User.
Based on the Technology of the market is segmented into Cleavable, Non-cleavable, Linker Technology, Payload Technology.
In 2022, the cleavable linker category generated the highest revenue share of 65.20%. The most widely utilized technology for an effective outcome of ADCs in cancer treatment is cleavable linkers, which allow ADCs to produce cytotoxins and stay stable in the bloodstream for longer. For instance, in 2020 the NMPA approved Seagen's & Takeda's Adcetris in China for the treatment of relapsed Hodgkin's lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL). The cleavable linker market segment is anticipated to be driven by these reasons throughout the forecast period.
The non-cleavable linker segment generated the second-highest revenue in 2022 because to the growing usage of Kadcyla, which has a non-cleavable linker. When producing ADCs that depend on lysosomal breakdown, non-cleavable linkers are employed to stop the drug's non-specific release, hence lowering the ADC's overall cytotoxicity to nearby healthy cells. Throughout the projection time, this is anticipated to propel the segment. At the moment, non-cleavable linkers are only used by FDA-approved ADCs like Blenrep and Kadcyla to bind the cytotoxic chemical and antibody.
Payloads, or cytotoxic substances, are used to specifically target and eliminate cancerous cells. A few of the payloads that are currently available on the market are microtubuline inhibitors (Vinorelbine, Paclitaxel, Epothilone B), tubulising (IM-2, B), DNA cleavers (Bleomycin A2), Akt inhibitors (GDC - 0068), DNA intercalators (Doxorubicin hydrochloride, Epirubicin hydrochloride, Duocarmycins, PBD dimers), MMAF & MMAE. In adult patients with relapsed multiple myeloma, GlaxoSmithKline plc's Blenrep (belantamab mafodotin-blmf) now uses MMAF, protease linker, and anti-CD38 monoclonal antibody to kill target cells.
Based on Application the market is segmented into Lymphoma, Ovarian Cancer, Lung Cancer, Breast Cancer, Brain Tumor, and Others.
Breast cancer had the largest revenue share in 2022 (50.61%), primarily as a result of the disease's comparatively high global incidence. According to World Health Organization predictions, there will be 685,000 cancer-related deaths and 2.26 million new cases of breast cancer worldwide in 2020. Three antibody-drug conjugate therapies are available for the treatment of breast cancer: Kadcyla from Hoffmann-La Roche Ltd., Enhertu from AstraZeneca, and Trodelvy from Gilead Sciences, Inc. If these drugs are made available through patient assistance programs, the market is expected to grow. Kadcyla offers financial assistance to eligible patients with private and governmental insurance.
The market for blood cancer is anticipated to expand at a CAGR of 10.7% over the projected period. Blood cancer ranks second worldwide in terms of cancer-related mortality and is the fifth most frequent type of cancer. The National Foundation of Cancer Research reports that in 2021, there were 186,400 new instances of leukemia, lymphoma, and myeloma diagnosed in the United States. It is also anticipated that the approval of several products over the course of the projection period will propel market expansion. For example, in October 2019, a novel medication called Polivy was introduced to the market to treat diffuse large B-cell lymphoma (DLBCL).
By region, Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. North America dominated the market in 2022 with a revenue share of 53.29%. increased per capita healthcare costs, increased cancer prevalence, and well-established research facilities for the development of novel ADCs are the main causes of the region's supremacy. The American Cancer Society projects that in 2022 there will be 1.9 million new instances of cancer in the US, which would result in around 609,360 deaths from the disease. It is expected that market expansion will be fueled by the region's acceptance of new ADCs. For instance, the U.S. FDA authorized Tidvak in September 2021 for the treatment of adult individuals with recurrent or metastatic cervical cancer.
The Asia Pacific antibody-drug conjugates market is projected to grow at a compound annual growth rate (CAGR) of 12.9% during the forecast period. The region's growth is due to the approval of additional ADCs in the area. As an illustration, Japan's MHLW gave Astellas's enfortumab vedotin priority review in May 2021 for the treatment of locally or metastatically advanced urothelial cancer.
Points Covered in the Report:
The points that are discussed within the report are-
Key Questions Answered:
Want to Review Complete Market Research Report
Customize this Report
Related Reports
Fractional Flow Reserve Market Size, Global Growth Trends, Forecast Report- Industry Outlook to 2031
March, 12:00 PM 10-MarDermatological Drugs Market Size, Growth, Trend & Forecast Report, (2024-2032)
March, 12:00 PM 10-Mar